Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04−1.16 (-36.25%)
Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –
Kyntra Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kyntra Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.05M. For fiscal 2025 it was -$4.77M. The highest annual figure on record is $81.60M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.77M | – |
| FY2024 | Dec 31, 2024 | -$138.00M | – |
| FY2023 | Dec 31, 2023 | -$315.02M | – |
| FY2022 | Dec 31, 2022 | -$145.93M | – |
| FY2021 | Dec 31, 2021 | -$82.23M | -200.8% |
| FY2020 | Dec 31, 2020 | $81.60M | – |
| FY2019 | Dec 31, 2019 | -$78.71M | – |
| FY2018 | Dec 31, 2018 | -$76.14M | – |
| FY2017 | Dec 31, 2017 | -$66.51M | -1035.7% |
| FY2016 | Dec 31, 2016 | $7.11M | – |
| FY2015 | Dec 31, 2015 | -$18.57M | -182.9% |
| FY2014 | Dec 31, 2014 | $22.41M | -13.5% |
| FY2013 | Dec 31, 2013 | $25.92M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.99M | -131.5% |
| Q1 FY2026 | Mar 31, 2026 | -$13.89M | -610.7% |
| Q4 FY2025 | Dec 31, 2025 | -$18.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.85M | – |
| Q2 FY2025 | Jun 30, 2025 | $12.68M | – |
| Q1 FY2025 | Mar 31, 2025 | $2.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -$84.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$110.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$101.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$51.88M | -217.2% |
| Q2 FY2022 | Jun 30, 2022 | -$33.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$54.96M | – |
| Q3 FY2021 | Sep 30, 2021 | $44.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.54M | -117.7% |
| Q1 FY2021 | Mar 31, 2021 | -$44.98M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.35M | – |
| Q2 FY2020 | Jun 30, 2020 | $149.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$59.49M | -364.6% |
| Q4 FY2019 | Dec 31, 2019 | -$45.05M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.48M | -433.2% |
| Q2 FY2019 | Jun 30, 2019 | -$28.65M | – |
| Q1 FY2019 | Mar 31, 2019 | $22.48M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.47M | – |
| Q3 FY2018 | Sep 30, 2018 | $8.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -$34.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$31.96M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.19M | – |
| Q3 FY2017 | Sep 30, 2017 | -$18.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.76M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.14M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.77M | – |
See a number that looks wrong?